why choose us

300×250 Ad Slot

Research Article: Efficacy of rFIXFc versus N-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM Trials

Date Published: 2023-07-27

Introduction:
For patients with hemophilia B, extended half-life (EHL) factor IX (FIX) products are available for both preventing (prophylaxis) and treating bleeds. These EHL agents display between - and -fold extension in mean terminal half-life compared with standard FIX products. Consequently, EHL FIX-based therapies offer the chance of prolonging dosing intervals between injections, to reduce treatment-related burden while improving bleed protection, thus satisfying most individual patients’ needs with favorable short- and…

Read more

300×250 Ad Slot